• HY, historically considered an initiating event in MM, can be preceded by deletions involving driver genes.

  • Deletions within large chromosomal gains represent a novel mechanism that impacts both driver gene expression and clinical outcomes.

Abstract

Acquisition of a hyperdiploid (HY) karyotype or immunoglobulin heavy chain (IgH) translocations are considered key initiating events in multiple myeloma (MM). To explore if other genomic events can precede these events, we analyzed whole-genome sequencing data from 1173 MM samples. By integrating molecular time and structural variants within early chromosomal duplications, we indeed identified pregain deletions in 9.4% of patients with an HY karyotype without IgH translocations, challenging acquisition of an HY karyotype as the earliest somatic event. Remarkably, these deletions affected tumor suppressor genes (TSGs) and/or oncogenes in 2.4% of patients with an HY karyotype without IgH translocations, supporting their role in MM pathogenesis. Furthermore, our study points to postgain deletions as novel driver mechanisms in MM. Using multiomics approaches to investigate their biologic impact, we found associations with poor clinical outcome in newly diagnosed patients and profound effects on both the oncogene and TSG activity despite the diploid gene status. Overall, this study provides novel insights into the temporal dynamics of genomic alterations in MM.

1.
Manier
S
,
Salem
KZ
,
Park
J
,
Landau
DA
,
Getz
G
,
Ghobrial
IM
.
Genomic complexity of multiple myeloma and its clinical implications
.
Nat Rev Clin Oncol
.
2017
;
14
(
2
):
100
-
113
.
2.
Rajkumar
SV
,
Landgren
O
,
Mateos
MV
.
Smoldering multiple myeloma
.
Blood
.
2015
;
125
(
20
):
3069
-
3075
.
3.
Kyle
RA
,
Rajkumar
SV
.
Monoclonal gammopathy of undetermined significance and smouldering multiple myeloma: emphasis on risk factors for progression
.
Br J Haematol
.
2007
;
139
(
5
):
730
-
743
.
4.
Landgren
O
,
Kyle
RA
,
Pfeiffer
RM
, et al
.
Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study
.
Blood
.
2009
;
113
(
22
):
5412
-
5417
.
5.
Maura
F
,
Bolli
N
,
Rustad
EH
,
Hultcrantz
M
,
Munshi
N
,
Landgren
O
.
Moving from cancer burden to cancer genomics for smoldering myeloma: a review
.
JAMA Oncol
.
2020
;
6
(
3
):
425
-
432
.
6.
Maura
F
,
Landgren
O
,
Morgan
GJ
.
Designing evolutionary-based interception strategies to block the transition from precursor phases to multiple myeloma
.
Clin Cancer Res
.
2021
;
27
(
1
):
15
-
23
.
7.
Barwick
BG
,
Gupta
VA
,
Vertino
PM
,
Boise
LH
.
Cell of origin and genetic alterations in the pathogenesis of multiple myeloma
.
Front Immunol
.
2019
;
10
:
1121
.
8.
Bergsagel
PL
,
Chesi
M
,
Nardini
E
,
Brents
LA
,
Kirby
SL
,
Kuehl
WM
.
Promiscuous translocations into immunoglobulin heavy chain switch regions in multiple myeloma
.
Proc Natl Acad Sci U S A
.
1996
;
93
(
24
):
13931
-
13936
.
9.
Bergsagel
PL
,
Kuehl
WM
.
Molecular pathogenesis and a consequent classification of multiple myeloma
.
J Clin Oncol
.
2005
;
23
(
26
):
6333
-
6338
.
10.
Bergsagel
PL
,
Kuehl
WM
,
Zhan
F
,
Sawyer
J
,
Barlogie
B
,
Shaughnessy
J
.
Cyclin D dysregulation: an early and unifying pathogenic event in multiple myeloma
.
Blood
.
2005
;
106
(
1
):
296
-
303
.
11.
Chesi
M
,
Bergsagel
PL
.
Molecular pathogenesis of multiple myeloma: basic and clinical updates
.
Int J Hematol
.
2013
;
97
(
3
):
313
-
323
.
12.
Chesi
M
,
Bergsagel
PL
,
Brents
LA
,
Smith
CM
,
Gerhard
DS
,
Kuehl
WM
.
Dysregulation of cyclin D1 by translocation into an IgH gamma switch region in two multiple myeloma cell lines
.
Blood
.
1996
;
88
(
2
):
674
-
681
.
13.
Chesi
M
,
Nardini
E
,
Brents
LA
, et al
.
Frequent translocation t(4;14)(p16.3;q32.3) in multiple myeloma is associated with increased expression and activating mutations of fibroblast growth factor receptor 3
.
Nat Genet
.
1997
;
16
(
3
):
260
-
264
.
14.
Fonseca
R
,
Debes-Marun
CS
,
Picken
EB
, et al
.
The recurrent IgH translocations are highly associated with nonhyperdiploid variant multiple myeloma
.
Blood
.
2003
;
102
(
7
):
2562
-
2567
.
15.
Smadja
NV
,
Leroux
D
,
Soulier
J
, et al
.
Further cytogenetic characterization of multiple myeloma confirms that 14q32 translocations are a very rare event in hyperdiploid cases
.
Genes Chromosomes Cancer
.
2003
;
38
(
3
):
234
-
239
.
16.
Maura
F
,
Kaddoura
M
,
Poos
AM
, et al
.
The temporal evolution of chromosome 1q gain and hyperdiploidy and its impact on clinical outcomes in multiple myeloma [abstract]
.
Blood
.
2023
;
142
(
suppl 1
):
638
.
17.
Maura
F
,
Rustad
EH
,
Yellapantula
V
, et al
.
Role of AID in the temporal pattern of acquisition of driver mutations in multiple myeloma
.
Leukemia
.
2020
;
34
(
5
):
1476
-
1480
.
18.
Lieber
MR
.
Mechanisms of human lymphoid chromosomal translocations
.
Nat Rev Cancer
.
2016
;
16
(
6
):
387
-
398
.
19.
Papaemmanuil
E
,
Rapado
I
,
Li
Y
, et al
.
RAG-mediated recombination is the predominant driver of oncogenic rearrangement in ETV6-RUNX1 acute lymphoblastic leukemia
.
Nat Genet
.
2014
;
46
(
2
):
116
-
125
.
20.
Machado
HE
,
Mitchell
E
,
Øbro
NF
, et al
.
Diverse mutational landscapes in human lymphocytes
.
Nature
.
2022
;
608
(
7924
):
724
-
732
.
21.
Bazarbachi
AH
,
Avet-Loiseau
H
,
Szalat
R
, et al
.
IgM-MM is predominantly a pre-germinal center disorder and has a distinct genomic and transcriptomic signature from WM
.
Blood
.
2021
;
138
(
20
):
1980
-
1985
.
22.
Walker
BA
,
Wardell
CP
,
Johnson
DC
, et al
.
Characterization of IGH locus breakpoints in multiple myeloma indicates a subset of translocations appear to occur in pregerminal center B cells
.
Blood
.
2013
;
121
(
17
):
3413
-
3419
.
23.
Maura
F
,
Ziccheddu
B
,
Xiang
JZ
, et al
.
Molecular evolution of classic Hodgkin lymphoma revealed through whole-genome sequencing of Hodgkin and reed Sternberg cells
.
Blood Cancer Discov
.
2023
;
4
(
3
):
208
-
227
.
24.
Nadeu
F
,
Martin-Garcia
D
,
Clot
G
, et al
.
Genomic and epigenomic insights into the origin, pathogenesis, and clinical behavior of mantle cell lymphoma subtypes
.
Blood
.
2020
;
136
(
12
):
1419
-
1432
.
25.
Maura
F
,
Rajanna
AR
,
Ziccheddu
B
, et al
.
Genomic classification and individualized prognosis in multiple myeloma
.
J Clin Oncol
.
2024
;
42
(
11
):
1229
-
1240
.
26.
Maura
F
,
Bolli
N
,
Angelopoulos
N
, et al
.
Genomic landscape and chronological reconstruction of driver events in multiple myeloma
.
Nat Commun
.
2019
;
10
(
1
):
3835
.
27.
Van Loo
P
,
Nordgard
SH
,
Lingjærde
OC
, et al
.
Allele-specific copy number analysis of tumors
.
Proc Natl Acad Sci U S A
.
2010
;
107
(
39
):
16910
-
16915
.
28.
Rustad
EH
,
Yellapantula
VD
,
Glodzik
D
, et al
.
Revealing the impact of structural variants in multiple myeloma
.
Blood Cancer Discov
.
2020
;
1
(
3
):
258
-
273
.
29.
Walker
BA
,
Mavrommatis
K
,
Wardell
CP
, et al
.
Identification of novel mutational drivers reveals oncogene dependencies in multiple myeloma
.
Blood
.
2018
;
132
(
6
):
587
-
597
.
30.
Zhang
Y
,
Yang
L
,
Kucherlapati
M
, et al
.
A pan-cancer compendium of genes deregulated by somatic genomic rearrangement across more than 1,400 cases
.
Cell Rep
.
2018
;
24
(
2
):
515
-
527
.
31.
Gerstung
M
,
Jolly
C
,
Leshchiner
I
, et al
.
The evolutionary history of 2,658 cancers
.
Nature
.
2020
;
578
(
7793
):
122
-
128
.
32.
Rustad
EH
,
Yellapantula
V
,
Leongamornlert
D
, et al
.
Timing the initiation of multiple myeloma
.
Nat Commun
.
2020
;
11
(
1
):
1917
.
33.
Mai
EK
,
Goldschmid
H
,
Miah
K
, et al
.
Elotuzumab, lenalidomide, bortezomib, dexamethasone, and autologous haematopoietic stem-cell transplantation for newly diagnosed multiple myeloma (GMMG-HD6): results from a randomised, phase 3 trial
.
Lancet Haematol
.
2024
;
11
(
2
):
e101
-
e113
.
34.
Korde
N
,
Roschewski
M
,
Zingone
A
, et al
.
Treatment with carfilzomib-lenalidomide-dexamethasone with lenalidomide extension in patients with smoldering or newly diagnosed multiple myeloma
.
JAMA Oncol
.
2015
;
1
(
6
):
746
-
754
.
35.
Landgren
O
,
Hultcrantz
M
,
Diamond
B
, et al
.
Safety and effectiveness of weekly carfilzomib, lenalidomide, dexamethasone, and daratumumab combination therapy for patients with newly diagnosed multiple myeloma: the MANHATTAN nonrandomized clinical trial
.
JAMA Oncol
.
2021
;
7
(
6
):
862
-
868
.
36.
Maura
F
,
Boyle
EM
,
Coffey
D
, et al
.
Genomic and immune signatures predict clinical outcome in newly diagnosed multiple myeloma treated with immunotherapy regimens
.
Nat Cancer
.
2023
;
4
(
12
):
1660
-
1674
.
37.
Poos
AM
,
Giesen
N
,
Catalano
C
, et al
.
Comprehensive comparison of early relapse and end-stage relapsed refractory multiple myeloma [abstract]
.
Blood
.
2020
;
136
(
suppl 1
):
1
.
38.
Poos
AM
,
Prokoph
N
,
Przybilla
MJ
, et al
.
Resolving therapy resistance mechanisms in multiple myeloma by multiomics subclone analysis
.
Blood
.
2023
;
142
(
19
):
1633
-
1646
.
39.
Aaltonen
LA
,
Abascal
F
,
Abeshouse
A
, et al
.
Pan-cancer analysis of whole genomes
.
Nature
.
2020
;
578
(
7793
):
82
-
93
.
40.
Alexandrov
LB
,
Kim
J
,
Haradhvala
NJ
, et al
.
The repertoire of mutational signatures in human cancer
.
Nature
.
2020
;
578
(
7793
):
94
-
101
.
41.
Bolli
N
,
Maura
F
,
Minvielle
S
, et al
.
Genomic patterns of progression in smoldering multiple myeloma
.
Nat Commun
.
2018
;
9
(
1
):
3363
.
42.
Kasar
S
,
Kim
J
,
Improgo
R
, et al
.
Whole-genome sequencing reveals activation-induced cytidine deaminase signatures during indolent chronic lymphocytic leukaemia evolution
.
Nat Commun
.
2015
;
6
:
8866
.
43.
Merelli
I
,
Guffanti
A
,
Fabbri
M
, et al
.
RSSsite: a reference database and prediction tool for the identification of cryptic recombination signal sequences in human and murine genomes
.
Nucleic Acids Res
.
2010
;
38
(
Web Server issue
):
W262
-
W267
.
44.
Affer
M
,
Chesi
M
,
Chen
WDG
, et al
.
Promiscuous MYC locus rearrangements hijack enhancers but mostly super-enhancers to dysregulate MYC expression in multiple myeloma
.
Leukemia
.
2014
;
28
(
8
):
1725
-
1735
.
45.
Dentro
SC
,
Leshchiner
I
,
Haase
K
, et al
.
Characterizing genetic intra-tumor heterogeneity across 2,658 human cancer genomes
.
Cell
.
2021
;
184
(
8
):
2239
-
2254.e39
.
You do not currently have access to this content.
Sign in via your Institution